Medicine and Dentistry
Inflammatory Bowel Disease
100%
Diagnosis
57%
Cohort Analysis
56%
Patient with Inflammatory Bowel Disease
50%
Patient Registry
50%
Vedolizumab
50%
Biological Therapy
50%
Elderly Patient
50%
Obstructive Lung Disease
50%
Ulcerative Colitis
50%
Crohn's Disease
50%
Tumor Necrosis Factor
50%
Contraindication
50%
Hazard Ratio
11%
Medical Record
9%
Bronchiectasis
7%
Chronic Obstructive Pulmonary Disease
7%
Asthma
7%
Odds Ratio
7%
Adverse Event
6%
Multivariate Analysis
6%
Patient with Ulcerative Colitis
6%
Keyphrases
Inflammatory Bowel Disease
100%
Population-based Cohort Study
50%
Vedolizumab
50%
Obstructive Lung Disease
50%
Population-based
50%
Confidence Interval
28%
Steroid-free
16%
Disease Onset
15%
Disease Diagnosis
14%
Adjusted Hazard Ratio
11%
Denmark
10%
Asthma
7%
Time-to-event Analysis
7%
Chronic Obstructive Pulmonary Disease
7%
Bronchiectasis
7%
Sensitivity Analysis
7%
Non-penetrating
5%
Pharmacology, Toxicology and Pharmaceutical Science
Inflammatory Bowel Disease
50%
Cohort Study
50%
Chronic Obstructive Lung Disease
50%
Vedolizumab
50%
Bronchiectasis
7%
Asthma
7%